+ |
Bafetinib | down-regulates
chemical inhibition
|
LYN |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-190227 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
Bafetinib | down-regulates
chemical inhibition
|
BCR-ABL |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-190224 |
|
|
Homo sapiens |
|
pmid |
sentence |
Other |
|
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
Bafetinib | down-regulates activity
chemical inhibition
|
BCR-ABL |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-255819 |
|
|
Homo sapiens |
|
pmid |
sentence |
21154127 |
Bafetinib (NS-187, INNO-406) is a second-generation tyrosine kinase inhibitor in development by CytRx under license from Nippon Shinyaku for treating Bcr-Abl+ leukemia's, including chronic myelogenous leukemia (CML) and Philadelphia+ acute lymphoblastic leukemia. It is a rationally developed tyrosine kinase inhibitor based on the chemical structure of imatinib, with modifications added to improve binding and potency against Bcr-Abl kinase. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |